<DOC>
	<DOC>NCT00772499</DOC>
	<brief_summary>The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.</brief_summary>
	<brief_title>Vascular Improvement With Olmesartan Medoxomil Study</brief_title>
	<detailed_description />
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>Male or female 1875 years of age Mean seated diastolic BP 90109 or mean seated systolic BP of 140179 Secondary hypertension Renal disease Diabetes mellitus Serum creatinine &gt;3.0 mg/dL Hemoglobin &lt;10 mg/dL (males) or &lt;9mg/dL (females) WBC count &lt;2000 cells/mL Platelet count &lt;100,000 cells/mL Either ALT &amp; AST &gt;2.5 x upper limit of normal BMI &gt;35 kg/m2 TIA or cerebrovascular attack within 3 months of study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>